AbbVie and argenx entered a collaboration for ARGX-115 (ABBV-151), a preclinical anti-GARP cancer immunotherapy. AbbVie paid $40M upfront plus up to $20M near-term preclinical milestones. argenx eligible for up to $625M in additional development, regulatory, and commercial milestones plus tiered double-digit royalties. AbbVie also received option to license additional immune checkpoint targets.
Key facts
AnnouncedApr 26, 2016
ClosedApr 26, 2016
Deal value$685M
Deal typeCo-Development
Therapeutic areaSolid tumors (immuno-oncology)
IndicationsSolid tumors (immuno-oncology)
Key assetsARGX-115 (ABBV-151)
MechanismAnti-GARP (glycoprotein A repetitions predominant) monoclonal antibody